Immunodeficiency Disorders: When the Immune System Fails

Primary Immunodeficiency Disorders

Primary immunodeficiencies (PIDs) are caused by mutations in genes that control immune cell development, function, or regulation. They are individually rare but collectively significant, with an estimated prevalence of 1 in 1,200 to 1 in 2,000 live births. Most follow Mendelian inheritance patterns, and advances in genetic sequencing have accelerated the discovery of new PIDs, with the number of recognized disorders more than doubling since 2010.

Severe combined immunodeficiency (SCID) is the most severe form of PID, characterized by the absence or dysfunction of both T cells and B cells. Infants with SCID appear healthy at birth, protected by maternal antibodies transferred across the placenta, but develop life-threatening infections within the first months of life as maternal antibodies wane. Without treatment, SCID is uniformly fatal, usually within the first year. The most common form, X-linked SCID, is caused by mutations in the IL2RG gene encoding the common gamma chain of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors. Without functional IL-7 signaling, T cells cannot develop in the thymus. The absence of T cell help means B cells cannot produce effective antibodies, even though B cells may be present in normal numbers.

Newborn screening for SCID using the T cell receptor excision circle (TREC) assay has been implemented in all 50 US states since 2018. TRECs are small circular DNA fragments generated during T cell receptor gene rearrangement in the thymus. Infants with SCID have few or no TRECs in their blood, allowing detection before the onset of life-threatening infections. Early diagnosis enables hematopoietic stem cell transplantation (bone marrow transplant) before the infant is weakened by infections, improving survival rates from below 50 percent (when diagnosed after symptomatic presentation) to above 90 percent (when diagnosed by newborn screening).

Common variable immunodeficiency (CVID) is the most frequently diagnosed symptomatic PID in adults, with a prevalence of approximately 1 in 25,000 to 1 in 50,000. CVID is characterized by low levels of IgG and IgA (and often IgM), impaired antibody responses to vaccination, and recurrent bacterial infections, particularly sinopulmonary infections caused by Streptococcus pneumoniae and Haemophilus influenzae. Unlike SCID, CVID usually does not manifest until the second or third decade of life, and its genetic basis is heterogeneous, with mutations in over 30 different genes identified in subsets of patients. Many cases remain genetically unexplained. Treatment consists of lifelong immunoglobulin replacement therapy, either intravenous (IVIG) or subcutaneous, typically administered every 2 to 4 weeks.

X-linked agammaglobulinemia (XLA), first described by Ogden Bruton in 1952, is caused by mutations in the BTK gene that encodes Bruton's tyrosine kinase, an enzyme essential for B cell development in the bone marrow. Boys with XLA have virtually no B cells or antibodies in their blood because B cell precursors arrest at the pre-B cell stage and cannot mature. They experience recurrent bacterial infections beginning around 6 months of age, when maternal antibodies have declined. T cell function is normal, so viral infections are generally handled normally. Treatment is lifelong immunoglobulin replacement.

Chronic granulomatous disease (CGD) represents a different category of PID: phagocyte function defects. In CGD, neutrophils and macrophages can engulf bacteria normally but cannot kill them because of mutations in the NADPH oxidase complex that generates the reactive oxygen species (superoxide, hydrogen peroxide, hypochlorous acid) required for intracellular killing. Patients with CGD develop recurrent infections with catalase-positive organisms, bacteria and fungi that produce their own catalase enzyme to neutralize the small amount of hydrogen peroxide they generate internally. The most common pathogens are Staphylococcus aureus, Aspergillus species, Burkholderia cepacia, and Serratia marcescens. Characteristic granulomas (organized collections of immune cells attempting to wall off infections they cannot clear) form in the lungs, lymph nodes, liver, and gastrointestinal tract.

Secondary Immunodeficiency

Secondary (acquired) immunodeficiencies are far more common than primary immunodeficiencies and result from external factors that impair immune function. The most significant cause globally is HIV infection, but malnutrition, immunosuppressive medications, cancer, diabetes, extremes of age, and chronic stress all contribute to immune dysfunction.

HIV (human immunodeficiency virus) causes immunodeficiency by infecting and destroying CD4+ T helper cells, the central coordinators of adaptive immune responses. HIV binds to the CD4 receptor and a coreceptor (CCR5 or CXCR4) on the T cell surface, fuses with the cell membrane, and uses reverse transcriptase to convert its RNA genome into DNA that integrates into the host cell's genome. The integrated provirus can remain latent for years or become actively transcribed to produce new virus particles. During acute HIV infection, the virus replicates explosively, and CD4+ T cell counts can drop below 500 cells per microliter (normal range: 500 to 1,500). The immune system partially controls viral replication during the clinical latency period, but without treatment, CD4+ counts decline at a rate of approximately 50 to 80 cells per year.

AIDS (acquired immunodeficiency syndrome) is diagnosed when the CD4+ count falls below 200 cells per microliter or when certain opportunistic infections or cancers occur. At this stage, the immune system can no longer control microorganisms that healthy immune systems suppress effortlessly: Pneumocystis jirovecii pneumonia, Toxoplasma gondii encephalitis, Cryptococcus neoformans meningitis, cytomegalovirus retinitis, Mycobacterium avium complex infections, and Kaposi sarcoma (caused by human herpesvirus 8). Before the introduction of antiretroviral therapy, the median survival after an AIDS diagnosis was 12 to 18 months.

Antiretroviral therapy (ART) has transformed HIV from a death sentence into a manageable chronic condition. Modern ART regimens, typically combining two or three drugs that target different stages of the viral life cycle (reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors), suppress viral replication to undetectable levels in the blood, allow CD4+ T cell recovery, and restore immune function sufficiently to prevent opportunistic infections. People living with HIV who achieve and maintain an undetectable viral load on ART have a near-normal life expectancy and cannot transmit the virus sexually, a concept summarized as U=U (undetectable equals untransmittable). However, ART does not eliminate the latent viral reservoir, integrated proviruses in long-lived memory CD4+ T cells that persist indefinitely. Curative strategies targeting this reservoir are an active area of research.

Iatrogenic immunosuppression, deliberately induced by medications, is another major cause of secondary immunodeficiency. Organ transplant recipients take immunosuppressive drugs (tacrolimus, mycophenolate mofetil, corticosteroids) to prevent graft rejection, which simultaneously increases their risk of infections and certain cancers. Patients receiving chemotherapy for cancer experience temporary but severe immunosuppression, particularly neutropenia, that predisposes them to bacterial and fungal infections. Biologic therapies used for autoimmune diseases, including TNF-alpha inhibitors and anti-CD20 antibodies, suppress specific immune pathways and carry defined infection risks: TNF-alpha inhibitors increase susceptibility to tuberculosis, and rituximab (anti-CD20) impairs B cell function for 6 to 12 months after each treatment course.

Diagnosing Immunodeficiency

The clinical presentation of immunodeficiency depends on which component of the immune system is affected. T cell deficiencies present with opportunistic infections by intracellular pathogens: viruses (CMV, EBV, VZV), fungi (Candida, Pneumocystis), and intracellular bacteria (mycobacteria, Listeria). B cell and antibody deficiencies present with recurrent infections by encapsulated extracellular bacteria: Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. Phagocyte defects present with deep-seated bacterial and fungal abscesses. Complement deficiencies present with recurrent Neisseria infections or autoimmune disease.

The Jeffrey Modell Foundation's 10 warning signs of primary immunodeficiency provide a clinical screening tool: four or more new ear infections in a year, two or more serious sinus infections in a year, two or more months on antibiotics with little effect, two or more pneumonias within a year, failure of an infant to gain weight or grow normally, recurrent deep skin or organ abscesses, persistent thrush in the mouth or fungal infection on the skin, need for intravenous antibiotics to clear infections, a family history of primary immunodeficiency, and two or more deep-seated infections such as meningitis, osteomyelitis, or septicemia.

Laboratory evaluation begins with a complete blood count with differential (to identify lymphopenia, neutropenia, or abnormal cell morphology), quantitative immunoglobulin levels (IgG, IgA, IgM, IgE), and specific antibody responses to vaccine antigens (tetanus, pneumococcal polysaccharides). More specialized testing includes lymphocyte subset analysis by flow cytometry (CD3+, CD4+, CD8+ T cells, CD19+ B cells, CD16+CD56+ NK cells), lymphocyte proliferation assays, neutrophil oxidative burst testing (for CGD), complement functional assays (CH50, AH50), and genetic testing using next-generation sequencing panels targeting known PID genes.

Treatment Approaches

Treatment of immunodeficiency depends on the specific defect and ranges from prophylactic antimicrobials and immunoglobulin replacement to curative stem cell transplantation and gene therapy.

Immunoglobulin replacement is the mainstay of treatment for antibody deficiencies (CVID, XLA, and other B cell disorders). Pooled human IgG, collected from thousands of donors to provide a broad spectrum of pathogen-specific antibodies, is administered intravenously (every 3 to 4 weeks) or subcutaneously (weekly or biweekly). The goal is to maintain trough IgG levels above 500 mg/dL, which significantly reduces the frequency of respiratory infections. Patients on adequate immunoglobulin replacement typically experience a dramatic improvement in quality of life and a reduction in hospitalizations.

Hematopoietic stem cell transplantation (HSCT) is the definitive cure for many severe PIDs, including SCID, CGD, Wiskott-Aldrich syndrome, and certain combined immunodeficiencies. The procedure involves replacing the patient's defective immune system with healthy stem cells from a matched donor (ideally an HLA-identical sibling). Outcomes are best when transplantation is performed early in life, before the accumulation of infection-related organ damage. For SCID patients identified by newborn screening and transplanted before 3.5 months of age with a matched sibling donor, overall survival exceeds 95 percent.

Gene therapy has emerged as a curative option for patients lacking a suitable transplant donor. The approach involves harvesting the patient's own stem cells, inserting a functional copy of the mutated gene using a viral vector (typically a lentivirus), and infusing the corrected cells back into the patient. Gene therapy has been successfully used for X-linked SCID, adenosine deaminase-deficient SCID (ADA-SCID), Wiskott-Aldrich syndrome, and CGD. The FDA-approved gene therapy Strimvelis (for ADA-SCID) and the more recent lentiviral-based therapies represent a paradigm shift from donor-dependent transplantation to personalized genetic correction.